Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Article Type
- Clinical Trial1
- Clinical Study1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Ophthalmology1
Search Results
Sort by
- BookVernon E. Rose, Barbara Cohrssen, editors ; contributors, M. Berode [and others].Contents:
V. 1. Hazard recognition
v. 2. Evaluation and control
v. 3. Physical and biological agents
v. 4. Program management and specialty areas of practice.Digital Access Wiley v.1-4=, 2011 - ArticleBoger WP, Puliafito CA, Steinert RF, Langston DP.Ophthalmology. 1978 Mar;85(3):259-67.Timolol was used by 37 glaucoma patients from 1 to 18 months. Of those 37 patients, 31 used timolol for three months or longer and 7 used timolol for over one year. Timolol produced sustained reductions in intraocular pressure with continuous administration and did not induce miosis, accommodative spasm, or other annoying side effects. Systemic absorption produced a mild slowing of resting pulse rate. In some patients, timolol's ocular hypotensive effects are additive to miotics and carbonic anhydrase inhibitors.